Description: Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. The Company's activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine. The Company has completed Phase I safety studies of its product candidate in Europe. In pre-clinical testing, anatabine demonstrates anti-inflammatory activity in a range of in vitro and in vivo assays.
Home Page: www.rockcreekpharmaceuticals.com
2040 Whitfield Avenue
Sarasota,
FL
34243
United States
Phone:
844-727-0727
Officers
| Name | Title |
|---|---|
| Dr. Michael John Mullan MBBS (M.D.,), Ph.D. | Chairman, Chief Exec. Officer and Pres |
| Dr. Curtis Wright IV | Sr. VP and Medical & Clinical Director |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 2.4673 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |